Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jun;12(2):107-17.
doi: 10.1007/s11154-011-9183-3.

Male hormonal contraception: potential risks and benefits

Affiliations
Review

Male hormonal contraception: potential risks and benefits

Niloufar Ilani et al. Rev Endocr Metab Disord. 2011 Jun.

Abstract

An effective, safe, reversible, and acceptable method of contraception is an important component of reproductive health and provides the opportunity of shared responsibility for family planning for both partners. Female hormonal contraceptives have been proven to be safe, reversible, available and widely acceptable by different populations. In contrast, male hormonal contraception, despite significant progress showing contraceptive efficacy comparable to female hormonal methods during last three decades, has not yet led to an approved product. Safety of a pharmaceutical product is an appropriate concern but the majority of male hormonal contraceptive clinical trials have not reported significant short term safety concerns. While the absence of serious adverse effects is encouraging, the studies have been designed for efficacy endpoints not long term safety. In this review we summarize potential risks and benefits of putative male hormonal contraceptives on reproductive and non-reproductive organs. While the review covers what we believe will be the likely class of drugs used for male hormonal contraception a true assessment of long term risks and benefits cannot be achieved without an available product.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Clin Endocrinol Metab. 2003 Nov;88(11):5232-9 - PubMed
    1. J Urol. 1996 Aug;156(2 Pt 1):438-41; discussion 441-2 - PubMed
    1. Ann Intern Med. 2010 Nov 16;153(10):678-9 - PubMed
    1. Ann Intern Med. 2010 Nov 16;153(10):621-32 - PubMed
    1. Hum Reprod. 2002 Jun;17(6):1490-501 - PubMed

Publication types

LinkOut - more resources